1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BONESUPPORT HOLDING AB

BONESUPPORT HOLDING AB

319.80
SEK
+62.60
(+24.34%)
3.48EPS
59.89P/E
13.84BMarket Cap
Feb 18Next Earn
BONESUPPORT HOLDING AB
STO:BONEX
(Nasdaq Stockholm)

Recent

price

319.80

P/E

ratio

59.89

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
0.89
1.34
2.26
3.25
1.9
3
3.06
3.33
5.1
9.1
13.69
17.84
19.39
Revenue per Share
-1.1
-1.29
-2.38
-3.24
-3.46
-3.1
-1.72
-1.34
-1.06
3.77
2.04
2.16
3.53
Basic EPS, GAAP
-1.02
-1.44
-1.8
-2.82
-3.42
-3.24
-1.74
-1.36
-0.78
-0.37
0.91
3.28
3.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.94
0.44
0.74
8.97
5.38
2.41
6.26
4.14
4.17
8.38
11.05
13.17
14.5
Book Value per Share
-1.05
0.33
0.65
8.86
5.27
2.26
6.12
4.01
4.04
8.19
10.82
12.94
14.27
Tangible Book Value per Share
46
46
46
40
51
52
59
64
64
65
66
66
66
Basic Weighted Avg Shares
41
62
105
129
97
155
181
213
329
591
899
1,175
1,277
Sales/Revenue/Turnover
-105.15
-87.96
-85.84
-75.4
-181.65
-101.45
-53.19
-39.13
-20.56
3.83
16.44
23.63
23.37
Operating Margin (%)
1
1
1
1
2
8
8
8
9
10
11
12
8
Depreciation Expense
-51
-60
-110
-129
-176
-161
-101
-86
-68
245
134
142
232
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
22.52
28.75
18.37
Effective Tax Rate (%)
-124.67
-96.44
-105.35
-99.67
-182.57
-103.6
-56.07
-40.18
-20.73
41.45
14.88
12.1
18.21
Profit Margin (%)
13
14
114
442
269
107
381
247
249
273
478
632
741
Working Capital
63
- -
85
- -
- -
6
6
16
12
13
8
4
2
LT Debt
-44
20
34
451
279
124
399
266
269
545
727
867
950
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.57
20.17
28.43
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
20.78
17.83
27.14
Return on Capital (%)
- -
- -
-403.39
-53.13
-48.38
-79.96
-38.77
-25.74
-25.5
60.19
21.02
17.83
27.5
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
8
8
LT Borrowings
- -
- -
- -
LT Finance Leases
4
6
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
65
Market Capitalization
12,382
12,836
13,844

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
797
891
908
Cash, Cash Equivalents & STI
378
455
434
Accounts Receivable, Net
216
222
222
Inventories
145
156
168
Total Current Liabilities
164
174
167
Payables & Accruals
- -
- -
- -
ST Debt
7
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
153.34%
24.64%
19.22%
Free Cash Flow
-12.25%
-39.03%
260.66%
Net Income, GAAP
-44.14%
-106.91%
6.28%
Sales/Revenue/Turnover
37.97%
46.94%
30.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
184
220
238
257
899
2025
284
284
- -
313
1,175
2026
324
356
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.42
0.46
0.82
2.04
2025
0.16
0.81
- -
0.67
2.16
2026
0.81
1.24
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bonesupport Holding AB (publ) (Nasdaq Stockholm: BONEX) is a Sweden-based orthobiologics company founded in 1999 and headquartered in Lund that develops, manufactures and commercializes innovative injectable bio-ceramic bone graft substitutes based on the patented CERAMENT technology platform, which remodels to the patient's own bone within six to twelve months and elutes drugs such as antibiotics directly into bone voids; core products include CERAMENT BVF (bone void filler for trauma, revision arthroplasty and diabetic foot applications), CERAMENT G (gentamicin-eluting synthetic bone substitute for infection management), and CERAMENT V (vancomycin-eluting variant); the company serves orthopedic, trauma, spine, and infection-related surgical markets with customers including hospitals and surgeons primarily in North America (US segment), Europe and rest of world (EUROW segment including subsidiaries in the UK, Germany, Denmark, Switzerland, Spain and Italy). Products address fractures, bone voids and gaps caused by trauma, chronic osteomyelitis, disease or related surgery and are commercially available in the US, Europe, India, Malaysia, Oman and Singapore. In 2025, the company reported strong sales growth with Q3 net sales of SEK 294 million (up 24% reported, 34% at constant exchange rates) and nine-month total of SEK 862 million (up 34% reported, 41% constant exchange rates), driven by 28% US growth and new clinical evidence supporting penetration in revision arthroplasty alongside ongoing spine initiatives including recruitment of specialized distributors and regulatory preparation for CERAMENT G; Torbjörn Sköld assumed the CEO role on September 1 succeeding Emil Billbäck who transitioned to senior advisor; CERAMENT V US application transferred to FDA De Novo process for potential category-defining approval anticipated before year-end; and secured key US Medicare reimbursements via New Technology Add-On Payment and Transitional Pass-Through programs for CERAMENT G to enhance commercialization.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q4 2025 Earnings Call Transcript